SNTI
HEALTHCARESenti Biosciences Inc
$0.97+0.02 (+1.82%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SNTI Today?
No stock-specific AI insight has been generated for SNTI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.77$3.88
$0.97
Fundamentals
Market Cap$31M
P/E Ratio—
EPS$-2.73
Dividend Yield—
Dividend / Share—
ROE-2.2%
Profit Margin—
Debt / Equity—
Trading
Volume108K
Avg Volume (10D)—
Shares Outstanding31.1M
SNTI News
20 articles- Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026Yahoo Finance·Apr 13, 2026
- Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell TherapiesYahoo Finance·Apr 1, 2026
- Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateYahoo Finance·Mar 27, 2026
- Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer ConferenceYahoo Finance·Mar 23, 2026
- Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare ConferenceYahoo Finance·Mar 3, 2026
- Senti Biosciences to Present at TD Cowen 46th Annual Health Care ConferenceYahoo Finance·Feb 24, 2026
- Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy DevelopmentYahoo Finance·Feb 20, 2026
- Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)Yahoo Finance·Feb 11, 2026
- Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026Yahoo Finance·Feb 3, 2026
- Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT DesignationYahoo Finance·Jan 14, 2026
- Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare ConferenceYahoo Finance·Jan 9, 2026
- Senti Biosciences Announces New Employment Inducement GrantsYahoo Finance·Dec 18, 2025
- BC-Most Active StocksYahoo Finance·Dec 9, 2025
- Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid LeukemiaYahoo Finance·Dec 9, 2025
- Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety ProfileYahoo Finance·Dec 9, 2025
- Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ETYahoo Finance·Dec 4, 2025
- Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in DecemberYahoo Finance·Nov 13, 2025
- Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025Yahoo Finance·Nov 3, 2025
- Senti Bio to Present at Chardan's 9th Annual Genetic Medicines ConferenceYahoo Finance·Oct 16, 2025
- Senti Bio to Present at BioJapanYahoo Finance·Oct 6, 2025
All 20 articles loaded
Price Data
Open$0.95
Previous Close$0.95
Day High$0.96
Day Low$0.95
52 Week High$3.88
52 Week Low$0.77
52-Week Range
$0.77$3.88
$0.97
Fundamentals
Market Cap$31M
P/E Ratio—
EPS$-2.73
Dividend Yield—
Dividend / Share—
ROE-2.2%
Profit Margin—
Debt / Equity—
Trading
Volume108K
Avg Volume (10D)—
Shares Outstanding31.1M
About Senti Biosciences Inc
Senti Biosciences Inc (SNTI) is an innovative biotechnology company at the forefront of synthetic biology, dedicated to pioneering next-generation cell and gene therapies. Utilizing its proprietary GeneCircuit platform, the company is developing programmable therapies aimed at treating a spectrum of diseases, including cancer and genetic disorders, thereby enhancing the precision of personalized medicine. With a robust development pipeline and strong strategic partnerships, Senti is strategically positioned to drive advancements in engineered cell therapies, offering transformative solutions to address critical unmet medical needs in the biopharmaceutical sector.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—